Be part of our mission to disrupt the healthcare and democratize the data driven medicine! SOPHiA GENETICS is looking for a Data Management Intern to join the Clinical Operations (ClinOps) Team to support activities related to multimodal projects leveraging on the aggregation of clinical, biological, imaging and genomics data. Combining high-quality data for each individual to generate multimodal insights, SOPHiA GENETICS harnesses the power of advanced AI and machine learning models. You will gain and benefit from experience in clinical study management across a wide range of trainings and activities involvement (regulatory, data management, biostatistics, legal, quality, finance, etc). You will be joining an organisation with the patient at the heart of every decision and action, driven by purpose as we drive exponential growth.

Would you like to join a dynamic and exciting health-tech company that uses cutting edge technologies to deliver a world changing solution that has a direct impact on the lives of cancer and rare disease patients worldwide? Join our growing team in Pessac (near Bordeaux, France) and use your exceptional abilities and knowledge skills to help us deliver on our mission of democratizing Data-Driven Medicine. We are looking for a talented and motivated Data Scientist / Biostatistician in Pessac (near Bordeaux, France)! SOPHiA GENETICS introduced the SOPHiA DDM platform height years ago. Today, the solution not only enables to integrate and visualize multiple data modalities, such as clinical, biological, genomics or medical-image data, but also to process relevant multimodal features and obtain multimodal insights using statistical learning.

In our journey to impact patient lives, we are looking for a Junior Data Scientist (6 months Internship) to join our Data Science-Radiomics Research team in Pessac (33, Bordeaux). SOPHiA GENETICS aims at developing Data-driven medicine, by delivering pathology and treatment-specific multimodal predictive signatures to help clinician making their decisions in the patient care path. This multimodal approach relies on the aggregation of different types of medical data and on advanced machine learning and deep learning models to process and analyze them. The Data Science – Radiomics Research teams, based in Pessac (Gironde, France), are involved in a key project about lung cancer, for the purpose of predicting treatment response and patient survival. In this context, an intern position is open for February 2023, to develop specific deep-learning-based algorithms for medical image automatic processing.

"With MatchMaker at hand, we were able to replace our reliance on conventional molecular docking in our fl agship proteome screening platform Ligand Express," the blog post detailed. "MatchMaker also plays a critical role in our newly launched Ligand Design technology for multi-objective drug design. Taken together, Ligand Design and Ligand Express, our fi rst-generation off-target profi ling platform, offer a unique end-to-end AI-augmented drug discovery platform to design ad-vanced lead-like molecules while minimizing off-target effects." Turning speci c details into generalizable rules Molly Gibson, PhD, is the co-founder of Generate Bio-medicines, a biotech company that uses a machine learning platform called Generative Biology to expedite the discovery of protein-based drugs. The platform, which leverages statistics to uncover patterns linking amino acid sequence, structure, and function, is designed to expand the available search space for novel biomedicines.

AI, or artificial intelligence, has taken root in biotech. In this article, we explore its newfound niches in the industry. Artificial intelligence (AI) and machine learning (ML) have become ubiquitous in tech startups, fueled largely by the increasing availability and amount of data and cheaper, more powerful computers. Now, if you are a new tech startup, ML or AI capabilities represent your minimum ticket to enter the industry. Over the past few years, AI and ML have started to peek their heads into the realm of biotech, due to an analogous transformation of biotech data.

Switzerland based SaaS startup Sophia Genetics is hoping to give IBM Watson a run for its money in the healthcare diagnostics space. It's built a big data analytics platform that harnesses clinicians' medical expertise to enhance genomic diagnostic via AI algorithms -- leading, it says, to better and faster diagnoses for patients with diseases such as cancer. Hospitals that use the platform are intended to jointly benefit from expert-fed, algorithmic DNA sequencing diagnostic insights exactly because they are shared across the platform. So as the user-base scales -- it says it's adding 10 new hospitals each month -- Sophia Genetics' AIs get smarter and more accurate, and patients anywhere can benefit from the pooled knowledge. The company is announcing a $30 million Series D funding round today, adding UK-based VC firm Balderton Capital to its investor roster, along with 360 Capital Partners.

AI, or artificial intelligence, has taken root in biotech. In this article, a contributor explores its newfound niches in the industry. Artificial intelligence (AI) and machine learning (ML) have become ubiquitous in tech startups, fueled largely by the increasing availability and amount of data and cheaper, more powerful computers. Now, if you are a new tech startup, ML or AI capabilities represent your minimum ticket to enter the industry. Over the past few years, AI and ML have started to peek their heads into the realm of biotech, due to an analogous transformation of biotech data. We are beginning to see partnerships form between Big Pharma and biotech startups that employ AI and ML for drug discovery and other purposes.

AI, or artificial intelligence, has taken root in biotech. In this article, we explore its newfound niches in the industry. Artificial intelligence (AI) and machine learning (ML) have become ubiquitous in tech startups, fueled largely by the increasing availability and amount of data and cheaper, more powerful computers. Now, if you are a new tech startup, ML or AI capabilities represent your minimum ticket to enter the industry. Over the past few years, AI and ML have started to peek their heads into the realm of biotech, due to an analogous transformation of biotech data. We are beginning to see partnerships form between Big Pharma and biotech startups that employ AI and ML for drug discovery and other purposes.

Adopted by over 430 hospitals across 60 countries, SOPHiA AI has proven to be a robust and standardized decision support technology for clinicians. SOPHiA is the first AI to analyze over 200,000 patients' genomic profiles around the world. This illustrates the rapid adoption of this technology which is trusted by clinicians to support their clinical decisions. The recent use of digital technology in healthcare is creating a new world of opportunity to help better diagnose and treat patients. The development of Next-Generation Sequencing (NGS), in particular, promises to enhance patient care for patients suffering from hereditary diseases and cancer.

Sophia Genetics has received a CE-IVD mark for its molecular diagnostics test, which will improve the detection of leukemia. Swiss company Sophia Genetics is a leader in the field of data-driven medicine, with its artificial intelligence (AI) technology already been used to analyze the next-generation sequencing data of over 160,000 patients' around the world. Today, the company has received a CE-IVD mark for its molecular diagnostics tool, meaning it can be traded within the European single market. The technology reads the genome more precisely to improve the diagnosis of leukemia and boost the personalization of cancer care. By receiving a CE mark, the company now has permission to trade its product within the European single market as it has shown no adverse effects on human health or the environment.